Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

about

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Item

http://www.wikidata.org/entity/Q52668202

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Efficacy of histology-agnostic ...... bitors for refractory cancers.

@en

Efficacy of histology-agnostic ...... bitors for refractory cancers.

@nl

type

Item

label

Efficacy of histology-agnostic ...... bitors for refractory cancers.

@en

Efficacy of histology-agnostic ...... bitors for refractory cancers.

@nl

prefLabel

Efficacy of histology-agnostic ...... bitors for refractory cancers.

@en

Efficacy of histology-agnostic ...... bitors for refractory cancers.

@nl

P1476

Efficacy of histology-agnostic ...... ibitors for refractory cancers

@en

P2093

Alina Fuerea

http://www.w3.org/2001/XMLSchema#string

Anas Gazzah

http://www.w3.org/2001/XMLSchema#string

Andrea Varga

http://www.w3.org/2001/XMLSchema#string

Antoine Hollebecque

http://www.w3.org/2001/XMLSchema#string

Aurélien Marabelle

http://www.w3.org/2001/XMLSchema#string

Capucine Baldini

http://www.w3.org/2001/XMLSchema#string

Christophe Massard

http://www.w3.org/2001/XMLSchema#string

Eric Angevin

http://www.w3.org/2001/XMLSchema#string

Etienne Rouleau

http://www.w3.org/2001/XMLSchema#string

Jean Yves Scoazec

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular characterization of human colon and rectal cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Activating HER2 mutations in HER2 gene amplification negative breast cancer

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

HER2 activating mutations are targets for colorectal cancer treatment

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

P304

9741-9750

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24188

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29515767

http://www.w3.org/2001/XMLSchema#string

P932

5839398

http://www.w3.org/2001/XMLSchema#string